FDA Submission

SEND datasets have become an integral part of the review, analysis, and interpretation of nonclinical toxicology studies, and this will trend will only continue to grow. The SEND dataset creation process is challenging and often requires a combination of data integration and manual effort, making quality control a critical step to ensuring that these dataset packages are fit for use. On April 18, Senior Product Management Director Peggy Zorn delivered an information-packed presentation on best practices and recommendations for SEND dataset review and visualizations. Check out the recap!